查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1576809

整体焦虑症市场：按作用机制、定价策略、分销管道和医疗保健提供者划分 - 2025-2030 年全球预测

Generalized Anxiety Disorder Market by Mode Of Action (Gamma-Aminobutyric Acid Receptors, Norepinephrine Modulators, Serotonin Modulators), Pricing Strategy, Distribution Channel, Healthcare Providers - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 191 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年整体焦虑症市场价值为21.3亿美元，预计到2024年将达到22.3亿美元，复合年增长率为5.42%，预计到2030年将达到30.9亿美元。

整体焦虑症（GAD）是一种慢性精神疾病，其特征是对日常生活各个方面过度且无法控制的担忧，影响着全世界数百万人。其市场范围包括旨在管理和缓解症状的药品、行为健康服务和数位心理健康平台。人们对心理健康问题的认识不断提高，盛行率不断上升，因此需要有效的治疗，而经济不确定性和 COVID-19 大流行等全球压力因素又加剧了这个问题。应用范围从处方药到认知行为疗法，再到提供诊断和治疗支援的数位应用。最终使用者群体主要是青少年和成人，人们对儿科病例中广泛性焦虑症的认识不断提高。影响该市场的关键成长要素包括个人化医疗的进步、新兴的远距远端医疗产业以及消费者对正念和健康应用程式等非药物干预措施的强劲需求。开发综合治疗通讯协定和使用人工智慧进行个人化治疗方法存在潜在机会。然而，该市场面临一些限制，例如围绕心理健康的耻辱、治疗结果不一致以及可及性问题，特别是在欠发达地区。一个关键的挑战是确保监管部门的核准并遵守严格的健康指南。创新成长领域包括增强数位诊断工具、扩展人工智慧主导的治疗进展见解以及利用基因组学进行更有针对性的治疗。市场的本质是动态的，需要不断发展和适应新技术进步和整体护理模式。企业应专注于加强与医疗技术公司的合作，并扩大远端医疗服务，以解决医疗保健取得问题。此外，透过宣传活动提高公众意识和减少耻辱感也在市场扩张中发挥重要作用。透过优先考虑这些策略，公司可以有效地应对现有挑战，同时利用不断增长的需求。

主要市场统计
基准年[2023] 21.3亿美元
预测年份 [2024] 22.3亿美元
预测年份 [2030] 30.9亿美元
复合年增长率（%） 5.42%

市场动态：快速发展的整体焦虑症市场的关键市场洞察

供需的动态交互作用正在改变整体焦虑症市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，并了解消费行为及其对製造成本的影响，并更清楚地了解对采购趋势的影响。

  • 市场驱动因素
    • 远端医疗和远距精神病学服务的扩展将促进整体焦虑症的便捷治疗。
    • 政府的倡议和对心理健康计画的资助推动了市场成长
    • 透过将行为和心理疗法整合到治疗方法中来改善患者的治疗效果
    • 加强製药公司和研究机构之间的合作以开发先进的治疗方法
  • 市场限制因素
    • 有限的保险范围和报销问题影响了整体焦虑症的治疗
  • 市场机会
    • 由于整体焦虑症药物治疗方法的进步，市场潜力巨大
    • 探索针对焦虑症的正念和认知行为治疗应用程式
    • 对心理健康意识宣传活动的投资增加推动了焦虑相关产品的市场成长
  • 市场挑战
    • 围绕心理健康状况的社会耻辱影响患者的诊断和寻求治疗的行为

波特的五力：驾驭整体焦虑症市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解整体焦虑症市场的外部影响

外部宏观环境因素在塑造整体焦虑症市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解整体焦虑症市场的竞争格局

整体焦虑症市场的详细市场占有率分析可以对供应商绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV整体焦虑症市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估整体焦虑症市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了整体焦虑症市场的成功之路

对于旨在加强其在全球市场的影响力的公司来说，对整体焦虑症市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 远端医疗和远距精神病学服务的扩展有利于整体焦虑症的便捷治疗
      • 政府的倡议和对心理健康计画的资助推动了市场成长
      • 将行为和心理治疗纳入治疗计划，以改善患者的治疗效果
      • 加强製药公司与研究机构的合作，开发先进的治疗方法
    • 抑制因素
      • 保险范围限制和报销问题限制了整体焦虑症治疗的机会
    • 机会
      • 由于整体焦虑症药物治疗的进展，预计会有较高的市场销路
      • 焦虑症正念和认知行为治疗应用程式的调查
      • 对心理健康意识宣传活动的投资增加推动了焦虑相关产品的市场成长
    • 任务
      • 围绕精神疾病的社会耻辱影响患者的诊断和寻求治疗的行为
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章整体焦虑障碍的市场机制

  • γ-胺基丁酸 (GABA) 受体
  • 去甲肾上腺素调节剂
  • 血清素调节剂

第七章整体焦虑症市场价格策略

  • 经济舱票价
  • 渗透定价
  • 溢价

第八章整体焦虑症市场：按分销管道

  • 医院
  • 网路药房
  • 零售药房

第九章医疗保健专业人员的整体焦虑症市场

  • 基层医疗医生
  • 精神科医生
  • 治疗师

第10章：美洲整体焦虑症市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太整体焦虑症市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的整体焦虑症市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议
Product Code: MRR-1A1A064C03B0

The Generalized Anxiety Disorder Market was valued at USD 2.13 billion in 2023, expected to reach USD 2.23 billion in 2024, and is projected to grow at a CAGR of 5.42%, to USD 3.09 billion by 2030.

Generalized Anxiety Disorder (GAD) is a chronic mental health condition characterized by excessive and uncontrollable worry about various aspects of daily life, affecting millions worldwide. Its market scope encompasses pharmaceuticals, behavioral therapy services, and digital mental health platforms designed to manage and alleviate symptoms. The necessity for effective treatments stems from the heightened awareness and rising prevalence of mental health issues, amplified by global stressors such as economic uncertainties and the COVID-19 pandemic. Applications are manifold, ranging from prescription medications to cognitive-behavioral therapy and digital applications that offer diagnostic and therapeutic support. End-use demographics primarily include adolescents and adults, with a growing recognition of GAD in pediatric cases. Key growth factors influencing this market include advancements in personalized medicine, the burgeoning telehealth sector, and strong consumer demand for non-pharmacological interventions such as mindfulness and wellness apps. The potential opportunities exist in developing integrated treatment protocols and harnessing AI for personalized treatment regimens. However, the market faces limitations such as stigma surrounding mental health, inconsistent treatment efficacy, and accessibility issues, particularly in underdeveloped regions. A significant challenge is ensuring regulatory approvals and compliance with stringent health guidelines. Innovative areas for growth include the enhancement of digital diagnostic tools, expansion of AI-driven insights for therapeutic advancements, and leveraging genomics for better-targeted treatments. The nature of the market is dynamic, necessitating constant evolution and adaptation to emerging technological advances and holistic care models. Companies should focus on fostering collaborations with health-tech firms and expanding teletherapy offerings to address care accessibility issues. Additionally, increasing public awareness and reducing stigma through campaigns can play a critical role in market expansion. By prioritizing these strategies, businesses can capitalize on the growing demand while addressing existing challenges effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 2.13 billion
Estimated Year [2024] USD 2.23 billion
Forecast Year [2030] USD 3.09 billion
CAGR (%) 5.42%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Generalized Anxiety Disorder Market

The Generalized Anxiety Disorder Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
    • Government initiatives and funding for mental health programs boosting market growth
    • Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
    • Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
  • Market Restraints
    • Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
  • Market Opportunities
    • Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
    • Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
    • Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
  • Market Challenges
    • Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior

Porter's Five Forces: A Strategic Tool for Navigating the Generalized Anxiety Disorder Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Generalized Anxiety Disorder Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Generalized Anxiety Disorder Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Generalized Anxiety Disorder Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Generalized Anxiety Disorder Market

A detailed market share analysis in the Generalized Anxiety Disorder Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Generalized Anxiety Disorder Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Generalized Anxiety Disorder Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Generalized Anxiety Disorder Market

A strategic analysis of the Generalized Anxiety Disorder Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Generalized Anxiety Disorder Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Alkermes plc, Allergan plc, AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly and Company, GlaxoSmithKline plc, H. Lundbeck A/S, Jazz Pharmaceuticals plc, Johnson & Johnson, Merck & Co., Inc., Novartis International AG, Otsuka Holdings Co., Ltd., Pfizer Inc., Roche Holding AG, Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., and Vanda Pharmaceuticals Inc..

Market Segmentation & Coverage

This research report categorizes the Generalized Anxiety Disorder Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Mode Of Action, market is studied across Gamma-Aminobutyric Acid (GABA) Receptors, Norepinephrine Modulators, and Serotonin Modulators.
  • Based on Pricing Strategy, market is studied across Economy Pricing, Penetration Pricing, and Premium Pricing.
  • Based on Distribution Channel, market is studied across Hospitals, Online Pharmacies, and Retail Pharmacies.
  • Based on Healthcare Providers, market is studied across Primary Care Physicians, Psychiatrists, and Therapists.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Expansion of telemedicine and telepsychiatry services facilitating convenient treatment for generalized anxiety disorder
      • 5.1.1.2. Government initiatives and funding for mental health programs boosting market growth
      • 5.1.1.3. Integration of behavioral therapies and psychotherapies in treatment regimens enhancing patient outcomes
      • 5.1.1.4. Increasing collaborations between pharmaceutical companies and research institutions to develop advanced treatments
    • 5.1.2. Restraints
      • 5.1.2.1. Limited insurance coverage and reimbursement issues affecting access to generalized anxiety disorder treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in pharmacological treatments for generalized anxiety disorder yielding high market potential
      • 5.1.3.2. Exploration of mindfulness and cognitive-behavioral therapy apps targeting anxiety disorders
      • 5.1.3.3. Increasing investment in mental health awareness campaigns driving market growth in anxiety-related products
    • 5.1.4. Challenges
      • 5.1.4.1. Social stigma surrounding mental health conditions impacting patient diagnosis and treatment-seeking behavior
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Generalized Anxiety Disorder Market, by Mode Of Action

  • 6.1. Introduction
  • 6.2. Gamma-Aminobutyric Acid (GABA) Receptors
  • 6.3. Norepinephrine Modulators
  • 6.4. Serotonin Modulators

7. Generalized Anxiety Disorder Market, by Pricing Strategy

  • 7.1. Introduction
  • 7.2. Economy Pricing
  • 7.3. Penetration Pricing
  • 7.4. Premium Pricing

8. Generalized Anxiety Disorder Market, by Distribution Channel

  • 8.1. Introduction
  • 8.2. Hospitals
  • 8.3. Online Pharmacies
  • 8.4. Retail Pharmacies

9. Generalized Anxiety Disorder Market, by Healthcare Providers

  • 9.1. Introduction
  • 9.2. Primary Care Physicians
  • 9.3. Psychiatrists
  • 9.4. Therapists

10. Americas Generalized Anxiety Disorder Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generalized Anxiety Disorder Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generalized Anxiety Disorder Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Alkermes plc
  • 3. Allergan plc
  • 4. AstraZeneca plc
  • 5. Bristol-Myers Squibb Company
  • 6. Eli Lilly and Company
  • 7. GlaxoSmithKline plc
  • 8. H. Lundbeck A/S
  • 9. Jazz Pharmaceuticals plc
  • 10. Johnson & Johnson
  • 11. Merck & Co., Inc.
  • 12. Novartis International AG
  • 13. Otsuka Holdings Co., Ltd.
  • 14. Pfizer Inc.
  • 15. Roche Holding AG
  • 16. Sanofi S.A.
  • 17. Sun Pharmaceutical Industries Ltd.
  • 18. Takeda Pharmaceutical Company Limited
  • 19. Teva Pharmaceutical Industries Ltd.
  • 20. Vanda Pharmaceuticals Inc.

LIST OF FIGURES

  • FIGURE 1. GENERALIZED ANXIETY DISORDER MARKET RESEARCH PROCESS
  • FIGURE 2. GENERALIZED ANXIETY DISORDER MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERALIZED ANXIETY DISORDER MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. GENERALIZED ANXIETY DISORDER MARKET DYNAMICS
  • TABLE 7. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY GAMMA-AMINOBUTYRIC ACID (GABA) RECEPTORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY NOREPINEPHRINE MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY SEROTONIN MODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ECONOMY PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PENETRATION PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PREMIUM PRICING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRIMARY CARE PHYSICIANS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PSYCHIATRISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY THERAPISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 27. AMERICAS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 31. ARGENTINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 35. BRAZIL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 39. CANADA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 43. MEXICO GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 48. UNITED STATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 53. ASIA-PACIFIC GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57. AUSTRALIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61. CHINA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65. INDIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 69. INDONESIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 73. JAPAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 77. MALAYSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 81. PHILIPPINES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 85. SINGAPORE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 89. SOUTH KOREA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 93. TAIWAN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 97. THAILAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 101. VIETNAM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 106. EUROPE, MIDDLE EAST & AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 110. DENMARK GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 114. EGYPT GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 118. FINLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 122. FRANCE GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 126. GERMANY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 130. ISRAEL GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 134. ITALY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 138. NETHERLANDS GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 142. NIGERIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 146. NORWAY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 150. POLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 154. QATAR GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 158. RUSSIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 162. SAUDI ARABIA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 166. SOUTH AFRICA GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 170. SPAIN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 174. SWEDEN GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 178. SWITZERLAND GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 182. TURKEY GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED ARAB EMIRATES GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY MODE OF ACTION, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY PRICING STRATEGY, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 190. UNITED KINGDOM GENERALIZED ANXIETY DISORDER MARKET SIZE, BY HEALTHCARE PROVIDERS, 2018-2030 (USD MILLION)
  • TABLE 191. GENERALIZED ANXIETY DISORDER MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 192. GENERALIZED ANXIETY DISORDER MARKET, FPNV POSITIONING MATRIX, 2023